Author(s): Leblebicioglu Hakan | Bayirli Derya | Esen Saban | Sunbul Mustafa | Eroglu Cafer
Journal: Annals of Clinical Microbiology and Antimicrobials
ISSN 1476-0711
Volume: 1;
Issue: 1;
Start page: 3;
Date: 2002;
Original page
ABSTRACT
Abstract Hepatitis C virus (HCV) infection becomes chronic in about 85 % of individuals as demonstrated by the persistence of HCV. It is necesseray to treat acute hepatitis C infection. Interferon-α is generally used for the treatment of acute HCV infection. Case presentation A 55-year-old woman with a history of fatique and icter was diagnosed as acute hepatitis C virus infection. She was treated with interferon-α 2b 3 million unite sc three times in a week and ribavirin 1000 mg daily for 6 months. Within 2 weeks of therapy, the alanine aminotransferase (ALT) had became normal. At the end of the 3 months of therapy, HCV RNA was negative and remained negative 6 months after the end of interferon treatment (sustained response). Conclusion This report suggests that interferon-α 2b and ribavirin may have a role in treatment of acute hepatitis C virus infection.
Journal: Annals of Clinical Microbiology and Antimicrobials
ISSN 1476-0711
Volume: 1;
Issue: 1;
Start page: 3;
Date: 2002;
Original page
ABSTRACT
Abstract Hepatitis C virus (HCV) infection becomes chronic in about 85 % of individuals as demonstrated by the persistence of HCV. It is necesseray to treat acute hepatitis C infection. Interferon-α is generally used for the treatment of acute HCV infection. Case presentation A 55-year-old woman with a history of fatique and icter was diagnosed as acute hepatitis C virus infection. She was treated with interferon-α 2b 3 million unite sc three times in a week and ribavirin 1000 mg daily for 6 months. Within 2 weeks of therapy, the alanine aminotransferase (ALT) had became normal. At the end of the 3 months of therapy, HCV RNA was negative and remained negative 6 months after the end of interferon treatment (sustained response). Conclusion This report suggests that interferon-α 2b and ribavirin may have a role in treatment of acute hepatitis C virus infection.